glp 1 functional medicine GLP-1s Do Far More Than Weight Loss — A View Combining GLP-1 medications with functional

[DOI] [PubMed] [Google Scholar] 179

That data is real, peer-reviewed, and worth understanding before another month goes by

In addition, high AMP levels inhibit adenylate cyclase reducing cyclic AMP formation in response to glucagon, which also decreases glycogenolysis and gluconeogenesis (i.e., decreases glucagon activity) (49)

Brain food intake & body weight Liver gluconeogenesis & steatosis Muscle glucose uptake & metabolic flexibility Adipose inflammation, insulin sensitivity Preclinical results (mouse model) vs GLP-1/GIP alone: Greater body weight reduction Stronger blood glucose lowering Better insulin sensitivity Less hepatic glucose production BUT not ready for clinic: Early preclinical stage only Human safety unknown PPAR agonism has mixed CV/renal history If it translates to humans, this could redefine metabolic disease treatment beyond anything we have today

Desai and Levine reported that weight reductions in GLP-1 RA users were comparable to those observed in non-IBD matched controls [29,36], with greater reductions observed with Tirzepatide [29]

As we discussed above we are careful in our progression to try to minimize side effects